

INV. No. QLSR-INV-E-01749/(2024-2025)(1735)
Patient Name **RAKESH KUMAR**
Age/Gen 37 Years | Male
Referred By **Dr. Self**
Source BERLIN DIAG CGHS OSS* - (6)

Patient ID 1749
Invoice Generated 04/05/2024 12:16 PM
Sample Received 04/05/2024 12:16 PM
Report Generated 04/05/2024 04:34 PM



Report Of Biochemistry Examination

Investigation	Result	Unit(s)	Reference Range
GLUCOSE FASTING (FBS)			
Plasma Glucose(F) Method (GOD-POD Method)	78.2	mg/dL	65 - 110
Comments: Fasting Blood Sugar/Glucose test a blood sample will be taken after an overnight fast. A fasting blood sugar level of less than 100mg/dL is normal. A fasting blood sugar level from 100 to 125 mg/dL is considered prediabetes. If it's 126 mg/dL or higher on two separate tests, you have diabetes.			
LIPID PROFILE			
Serum Triglyceride Method (Enzymatic,end point)	110	mg/dL	< 150
Serum Cholesterol Method (Oxidase, Esterase, Peroxidase)	132	mg/dL	125 - 200
Serum HDL-Chol Method (PTA/MgC12, Reflectance photometry)	33	mg/dL	30 - 65
Serum LDL-Chol Method (Direct Homogeneous, Spectrophotometry)	77	mg/dL	85 - 150
Serum VLDL-Chol	22	mg/dL	5 - 40
Serum LDL/HDL Cholesterol Ratio Method (Calculated)	2.33		1.5 - 3.5
Serum Cholesterol/ HDL Ratio Method (Calculated)	4.00		Low Risk(0 - 3) High Risk(5 - 10)

Interpretation :

NATIONAL LIPID ASSOCIATION RECOMMENDATIONS (NLA-2014)	TOTAL CHOLESTEROL in mg/dL	TRIGLYCERIDE in mg/dL	LDL CHOLESTEROL in mg/dL	NON HDL CHOLESTEROL in mg/dL
Optimal	<200	<150	<100	<130
Above Optimal	-	-	100- 129	130 - 159
Borderline High	200-239	150-199	130-159	160 - 189
High	>=240	200-499	160-189	190 - 219
Very High	-	>=500	>=190	>=220

Note :

1. Measurements in the same patient can show physiological & analytical variations. Three serial samples



INV. No.	QLSR-INV-E-01749/(2024-2025)(1735)	Patient ID	1749
Patient Name	RAKESH KUMAR	Invoice Generated	04/05/2024 12:16 PM
Age/Gen	37 Years Male	Sample Received	04/05/2024 12:16 PM
Referred By	Dr. Self	Report Generated	04/05/2024 04:34 PM
Source	BERLIN DIAG CGHS OSS* - (6)		

Report Of Biochemistry Examination

Investigation	Result	Unit(s)	Reference Range
<p>1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.</p> <p>2. Lipid Association of India (LAI) recommends screening of all adults above the age of 20 years for Atherosclerotic Cardiovascular Disease (ASCVD) risk factors especially lipid profile. This should be done earlier if there is family history of premature heart disease, dyslipidemia, obesity or other risk factors.</p> <p>3. Indians tend to have higher triglyceride levels & Lower HDL cholesterol combined with small dense LDL particles, a pattern known as atherogenic dyslipidemia.</p> <p>4. Non HDL Cholesterol comprises the cholesterol carried by all atherogenic particles, including LDL, IDL, VLDL & VLDL remnants, Chylomicron remnants & Lp(a).</p> <p>5. LAI recommends LDL cholesterol as primary target and Non HDL cholesterol as co-primary treatment target.</p> <p>6. Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals have been achieved.</p> <p>7. Additional testing for Apolipoprotein B, hsCRP, Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement</p>			

LIVER PROFILE (LFT)

Serum Bilirubin (Total) <small>Method (By Diphylline, Diazonium Salt)</small>	0.30	mg/dL	0.2 - 1.3
Serum Bilirubin (Direct) <small>Method (Diphylline, Diazonium Salt)</small>	0.15	mg/dL	0.1 - 0.4
Serum Bilirubin (Indirect) <small>Method (Calculated)</small>	0.15	mg/dL	0.2 - 1.1
Serum SGOT <small>Method (IFCC)</small>	25.4	U/L	17 - 59
Serum SGPT <small>Method (IFCC)</small>	27.9	U/L	21 - 72
Alkaline phosphatase (ALP) <small>Method (IFCC)</small>	102.0	U/L	Adult (38 - 126)
Serum Total Protein <small>Method (Biuret Method)</small>	5.8	g/dL	Adult(6.2 - 8.2) Children(5.6 - 8.4)
Serum Albumin <small>Method (BCG, Dye Binding Method)</small>	4.0	gm/dL	Newborn Children(2.4 - 4.8) Adult(3.5 - 5.0)
Serum Globulin <small>Method (Calculated)</small>	1.80	g/dL	Adult(2.3 - 3.6)
Serum A/G Ratio <small>Method (BCG)</small>	2.22		1.0 - 2.3

Report ID:- 2625 | Page 2/3



Dr. R. Verma
 MBBS, MD(Pathology)

INV. No.	QLSR-INV-E-01749/(2024-2025)(1735)	Patient ID	1749
Patient Name	RAKESH KUMAR	Invoice Generated	04/05/2024 12:16 PM
Age/Gen	37 Years Male	Sample Received	04/05/2024 12:16 PM
Referred By	Dr. Self	Report Generated	04/05/2024 04:34 PM
Source	BERLIN DIAG CGHS OSS* - (6)		

Report Of Biochemistry Examination

Investigation	Result	Unit(s)	Reference Range
---------------	--------	---------	-----------------

Note

1. In an asymptomatic patient, Non alcoholic fatty liver disease (NAFLD) is the most common cause of increased AST, ALT levels. NAFLD is considered as hepatic manifestation of metabolic syndrome.
2. In most type of liver disease, ALT activity is higher than that of AST; exception may be seen in Alcoholic Hepatitis, Hepatic Cirrhosis, and Liver neoplasia. In a patient with Chronic liver disease, AST:ALT ratio>1 is highly suggestive of advanced liver fibrosis.
3. In known cases of Chronic Liver disease due to Viral Hepatitis B & C, Alcoholic liver disease or NAFLD, Enhanced liver fibrosis (ELF) test may be used to evaluate liver fibrosis.
4. In a patient with Chronic Liver disease, AFP and Des-gamma carboxyprothrombin (DCP)/PIVKA II can be used to assess risk for development of Hepatocellular Carcinoma.

KIDNEY FUNCTION TEST (KFT)

Serum Urea <small>Method (GLDH,Kinetic Assay)</small>	28.6	mg/dL	Adult (17 - 43) New Born (8.4 - 25.8) Infant (10.8 - 38.4)
Serum Creatinine <small>Method (Modified Jaffe, Kinetic)</small>	1.1	mg/dL	Male: (0.72-1.18) Neonate : (0.26 - 1.01) Infant { 2months - less than 3 yrs } : (0.15- 0.37) Children { 3 yrs - less than 15 yrs } : (0.24 -0.73)
Serum Uric Acid <small>Method (uricase-Colorimetric)</small>	4.7	mg/dL	3.5 - 8.5
Serum Sodium <small>Method (By Indirect ISE)</small>	140.5	mmol/L	136 - 145
Serum Potassium <small>Method (By Indirect ISE)</small>	4.5	mmol/L	3.5 - 5.1
Serum Chloride <small>Method (By Ion-selective Electrode)</small>	101.5	mmol/L	98 - 107

~~~~~ End of report ~~~~~



INV. No. QLSR-INV-E-01749/(2024-2025)(1735)  
Patient Name **RAKESH KUMAR**  
Age/Gen 37 Years | Male  
Referred By **Dr. Self**  
Source BERLIN DIAG CGHS OSS\* - (6)

Patient ID 1749  
Invoice Generated 04/05/2024 12:16 PM  
Sample Received 04/05/2024 12:16 PM  
Report Generated 04/05/2024 07:41 PM



### Report Of Biochemistry Examination

| Investigation                                 | Result | Unit(s) | Reference Range |
|-----------------------------------------------|--------|---------|-----------------|
| <b>GLUCOSE, POST PRANDIAL 2 HOURS</b>         |        |         |                 |
| Plasma Glucose(PP)<br>Method (GOD-POD Method) | 104    | mg/dL   | 75 - 140        |

**Note :**

1. The diagnosis of Diabetes requires a fasting plasma glucose of  $>$  or  $=$  126 mg/dL and/or a random / 2 hr post glucose value of  $>$  or  $=$  200 mg/dL on at least 2 occasions
2. Very low glucose levels cause severe CNS dysfunction
3. Very high glucose levels ( $>$ 450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical

~~~~~ End of report ~~~~~



INV. No. QLSR-INV-E-01749/(2024-2025)(1735)
Patient Name **RAKESH KUMAR**
Age/Gen 37 Years | Male
Referred By **Dr. Self**
Source BERLIN DIAG CGHS OSS* - (6)

Patient ID 1749
Invoice Generated 04/05/2024 12:16 PM
Sample Received 04/05/2024 12:16 PM
Report Generated 05/05/2024 12:21 PM



Report Of Haematology Examination

| Investigation | Result | Unit(s) | Reference Range |
|-------------------------|----------|---------|-----------------|
| BLOOD GROUP | | | |
| Whole blood Blood Group | "O" | | |
| Whole blood Rh Type | Positive | | |

Note:

- Both forward and reverse grouping performed.
- Test conducted on EDTA whole blood.

~~~~~ End of report ~~~~~



INV. No. QLSR-INV-E-01749/(2024-2025)(1735)  
Patient Name **RAKESH KUMAR**  
Age/Gen 37 Years | Male  
Referred By **Dr. Self**  
Source BERLIN DIAG CGHS OSS\* - (6)

Patient ID 1749  
Invoice Generated 04/05/2024 12:16 PM  
Sample Received 04/05/2024 12:16 PM  
Report Generated 05/05/2024 01:22 PM



### Report Of Biochemistry Examination

| Investigation                                                            | Result | Unit(s) | Reference Range                              |
|--------------------------------------------------------------------------|--------|---------|----------------------------------------------|
| <b>GLYCOSYLATED HAEMOGLOBIN</b>                                          |        |         |                                              |
| Whole blood HbA1c<br>Method (HPLC)                                       | 5.6    | %       | Non diabetic level( < 6.0 )<br>Goal( < 7.0 ) |
| Whole blood eAG (Estimated AverageGlucose Level)<br>Method (CALCULATION) | 114    | mg/dl   | -                                            |

**Note:**

**The Parameter indicates control over the last 90 Days**

In the Blood, glucose adheres to haemoglobin (Hb) and make Glycosylated haemoglobin/HbA<sub>1c</sub>, which provides a clue about the average blood glucose level over the last 8-12 weeks and it is an indicator for chronic glycaemic control along with effects of drug, diet and exercise.

In normal individuals, 90% is the adult haemoglobin fraction and the rest 8% is formed by HbA. Reduction of HbA<sub>1c</sub> value reduces diabetic and cardiological related morbidity and mortality.

The short life span of RBC in haemoglobinopathy and chemically modified derivatives of haemoglobin (carbamylated Hb in renal failure and acetylated Hb, who are taking aspirin) can affect the results. Iron deficiency anaemia, liver disease, opiate addiction may interfere the test value.

HPLC, ion exchange chromatography is the ideal method for HbA<sub>1c</sub> estimation. The target goal is <7%.

Besides HbA<sub>1c</sub> serum fructosamine can be measured.

**American diabetes association guideline**

**Reference range**

|                               |               |
|-------------------------------|---------------|
| Non diabetic adult > 18 years | : < 5.7%      |
| Pediabetes                    | : 5.7% - 6.4% |
| Diagnosing diabetes           | : > 6.5%      |

~~~~~ End of report ~~~~~



INV. No. QLSR-INV-E-01749/(2024-2025)(1735)
Patient Name **RAKESH KUMAR**
Age/Gen 37 Years | Male
Referred By **Dr. Self**
Source BERLIN DIAG CGHS OSS* - (6)

Patient ID 1749
Invoice Generated 04/05/2024 12:16 PM
Sample Received 04/05/2024 12:16 PM
Report Generated 04/05/2024 06:26 PM



Report Of Haematology Examination

| Investigation | Result | Unit(s) | Reference Range |
|---------------|--------|---------|-----------------|
|---------------|--------|---------|-----------------|

ERYTHROCYTE SEDIMENTATION RATE

| | | | |
|-------------------------------------|----|----|------|
| ESR
Method (Westergren & Manual) | 10 | mm | < 20 |
|-------------------------------------|----|----|------|

Note

1. C-Reactive Protein (CRP) is the recommended test in acute inflammatory conditions.
2. Test conducted on EDTA whole blood at 37°C.
3. ESR readings are auto- corrected with respect to Hematocrit (PCV) values

COMPLETE BLOOD COUNT

| | | | |
|--|-------------|--------------|--|
| Haemoglobin (Hb)%
Method (By Sahlis Method) | 13.6 | gm% | Adult Men (13 - 18)
Adult Women (11.5 - 16.5)
Children (11 - 13)
Children (1-6) : (12 - 14)
Children (6-12) : (12 - 14) |
| PCV | 46.9 | % | 35 - 45 |
| Total Platelets Count (PC) | 1.7 | Lacs Per cmm | 1.5 - 4 |
| Total RBC (Red Cell Count) | 5.2 | mill./uL | Women (4.2 - 5.4)
Male (4.7 - 6.1)
Children (4.6 - 4.8) |
| Total Leucocyte Count (TLC)
Method (Flow Cytometry) | 6,500 | Per cmm | Adult :- (4,000 - 11,000)
New Born (10,000 - 26,000)
(1-4) Years : (6,000 - 18,000)
(5-7) Years : (5,000 - 15,000)
(8-12) Years : (4,500 - 12,500) |
| MCV | 90 | fL | 76 - 96 |
| MCH | 25.9 | pg | 22 - 32 |
| MCHC | 28.9 | g/dL | 30 - 35 |
| Differential count of Leucocytes | | | |
| Neutrophils | 61 | % | 40 - 70 |
| Lymphocytes | 29 | % | 15 - 40 |
| Monocytes | 03 | % | 00 - 6 |
| Eosinophils | 07 | % | 0.5 - 7 |
| Basophils | 00 | % | 00 - 01 |

~~~~~ End of report ~~~~~



INV. No. QLSR-INV-E-01749/(2024-2025)(1735)  
Patient Name **RAKESH KUMAR**  
Age/Gen 37 Years | Male  
Referred By **Dr. Self**  
Source BERLIN DIAG CGHS OSS\* - (6)

Patient ID 1749  
Invoice Generated 04/05/2024 12:16 PM  
Sample Received 04/05/2024 12:16 PM  
Report Generated 05/05/2024 12:35 PM



### Report Of Immunology Examination

| Investigation               | Result | Unit(s) | Reference Range                                                                                                                                                                                                                                         |
|-----------------------------|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>(Thyroid Profile-I)</b>  |        |         |                                                                                                                                                                                                                                                         |
| Serum T3<br>Method (ECLIA)  | 1.47   | ng/mL   | (0.8 - 2.0)<br>11-15 Years ( 0.83 - 2.13 )<br>1-10 Years ( 0.94 - 2.69 )<br>1-12 Months ( 1.05 - 2.45 )<br>1-7 Days ( 0.36 - 3.16 )<br>1-4 Weeks ( 1.05 - 3.45 )                                                                                        |
| Serum T4<br>Method (ECLIA)  | 9.61   | µg/dL   | (5.1 - 14.1)<br>1-12 Months ( 5.9 - 16 )<br>1-7 Days ( 11 - 22 )<br>1-4 Weeks ( 8.2 - 17 )<br>1-10 Years ( 6.4 - 15 )                                                                                                                                   |
| Serum TSH<br>Method (ECLIA) | 4.91   | µIU/mL  | 11-15 Years ( 5.5 - 12 )<br>Up to 1 Week (0.7-11.0)<br>1 week-4 week (0.7- 11.0)<br>1-12 Months (0.7- 8.4)<br>1-19 Years (0.6-4.9)<br>19 Years Above (0.5-5.5)<br>1st Trimester (0.6 - 3.4)<br>2nd Trimester (0.37 - 3.6) 3rd<br>Trimester(0.38 - 4.04) |

Mild to moderate degree of elevation normal T3&T4 levels indicates impaired thyroid hormone reserves and indicates subclinical hypothyroidism.

Mild to moderate decrease with normal T3 & T4 indicates subclinical hyperthyroidism.

TSH measurement is used for screening & diagnosis of Euthyroidism, hypothyroidism & hyperthyroidism. Suppressed TSH (< 0.01 µ IU/ml) suggests diagnosis of hyperthyroidism.

Elevated concentration of TSH (>7 µ IU/ml) suggest diagnosis of hypothyroidism.



Please correlate clinically.

~~~~~ End of report ~~~~~

Report ID:- 2802 | Page 1/1




Dr. Debasish Sahoo
MD (Microbiologist)





| | | | |
|--------------|-------------------|----------------|-------------------------------|
| Patient Name | MR. RAKESH KUMAR | Requested By | MEDIWHEEL |
| MRN | BER/2024/OPD21957 | Procedure Date | 04.05.2024 |
| Age/Sex | 37Y/MALE | Hospital | BERLIN DIAGNOSTICS & DAY CARE |

USG WHOLE ABDOMEN

Liver : The liver is normal in size (14.8 cm) and outline. It shows a uniform echopattern. No obvious focal or diffuse pathology is seen. The intra and extra hepatic biliary passage are not dilated. The portal vein is normal in caliber at the porta hepatis.

Gall bladder : The gall bladder is not visualized (post cholecystectomy status).

CBD : The CBD is of normal caliber.

Pancreas : The pancreas is normal in size and echogenicity with distinct outline. No obvious focal lesion is seen.

Kidneys : Both kidneys were normal in position:

Right kidney measures 9.9 cm
Left Kidney measures 9.9 cm

The renal cortical thickness and corticomedullary differentiation were adequate on both sides. No evidence of renal calculus or hydronephrosis seen on either sides.

Spleen : The spleen is normal in size and echogenicity.

Urinary Bladder : The urinary bladder is normal in size. Its walls show a smooth outline. There is no evidence of any intraluminal or perivesical abnormality.

Prostate : The prostate is normal in size, measures (19.2 gm) and shows normal parenchymal echogenicity.

No significant probe tenderness in RIF.

No evidence of pleural effusion on either side.

No evidence of ascites or lymphadenopathy seen.


IMPRESSION : Normal study.

Please correlate clinically.

Dr. Ambuj Srivastav
M.D. Consultant Radiologist.

PA VIEW

K



RAKESH KUMAR AGE 37Y/M MEDIWHEEL BER/202421957 CHEST PA VIEW 04/05/2024
BERLIN DIAGNOSTICS & DAY CARE, BARIATU ROAD, RANCHI.



| | | | |
|--------------|--------------|---------------|---------------|
| Patient Name | RAKESH KUMAR | Patient ID | BER/202421957 |
| Age/Gender | 37Years / F | Study Date | 04-May-2024 |
| Referred By | MEDIWHEEL | Reported Date | 04-May-2024 |

X – RAY CHEST PA VIEW

FINDINGS :-

Both lung fields under vision appear normal.

Cardiac size appears normal.

Both costophrenic angles are clear.

Hilar regions are normal.

Both domes appear normal in position.

Bony thorax under vision appears normal.

IMPRESSION :- NORMAL STUDY.

Dr.Sunny Shrivani
MD Radiology REG-33548

Date Reported: 04-May-2024

ID:2024050411251722

Name:

2024-05-04 12:49:14

MR. RAJESH KUMAR AGARWAL



ID:2024050411251722

Name:

2024-05-04 12:49:14

| | |
|----------------------|----------|
| Heart Rate (bpm) | 71 |
| PR Interval (ms) | 164 |
| QRS Duration (ms) | 88 |
| QT/QTc Interval (ms) | 362/381 |
| P/QRS/T Axes (deg) | 40/44/17 |

Sinus rhythm

--- Interpretation made without knowing patient's gender/age ---

Normal ECG

Unconfirmed Diagnosis.

Dr. Krishn Murari Prasad
 MBBS, D.P. Cardiology

